NanoBridge System Enables Targeted Modification of Hard-to-Drug Proteins in Living Cells
Researchers developed NanoBridge, a platform that uses biological binders to direct enzymes toward specific proteins and modify their chemical structure in living cells. The system overcomes limitations of existing approaches by working with proteins that lack traditional drug-binding sites, including cancer-related proteins like KRAS and p53. This advance could accelerate both basic research into protein function and development of new therapeutic strategies.
Scientists have created NanoBridge, a modular platform for editing post-translational modifications (PTMs)—chemical changes that alter protein function—on endogenous proteins within living cells. The system uses biological binders to temporarily recruit a small protein tag to target proteins, which then enables heterobifunctional small molecules to recruit endogenous enzymes that perform the desired modifications. Unlike existing chemically induced proximity approaches, NanoBridge works with proteins that lack well-defined binding pockets, including disordered proteins. The researchers demonstrated the platform's versatility by using eight different protein binders to mediate targeted degradation, phosphorylation, and acetylation on three structurally diverse proteins: BCL11A, KRAS, and p53. The modifications were rapid, reversible, and temporally controlled, suggesting NanoBridge could be valuable for both investigating protein biology and developing targeted therapeutics.
What's missing
The study does not discuss potential off-target effects, cellular toxicity, or scalability challenges for therapeutic applications. It also does not address how the approach compares quantitatively to alternative emerging methods for modifying challenging proteins, or provide information on whether the system has been tested in animal models or clinical contexts.
What different sources said
- bioRxivCenter
The NanoBridge system for targeted post-translational modification of challenging proteins
Related
Study Shows Statins Reduce Coenzyme Q in Brain Cells, Impairing Mitochondrial Function
A laboratory study found that statin drugs decrease coenzyme Q levels in astrocytes (brain support cells) by 30-40%, reducing their mitochondrial energy production and increasing oxidative stress. Astrocytes are critical for maintaining brain health and protecting neurons from damage. The findings suggest CoQ10 supplementation may help counteract these effects, though human clinical evidence remains limited.
Study reveals zebrafish larvae exhibit slowly fluctuating directional swim biases driven by internal dynamics
Researchers found that 5-day-old zebrafish larvae display changing directional swim preferences over many hours even in stable environments, contrary to classical models assuming constant individual biases. Computational analysis suggests these fluctuations arise from a non-stationary Markovian process with two independent internal input streams modulating swim direction repetition. The findings suggest animals possess intrinsic mechanisms for generating behavioral variability independent of external stimuli, with implications for understanding how internal states shape adaptive behavior.
Two Small Molecules Show Promise as Broad-Spectrum Coronavirus Inhibitors in Laboratory Study
Researchers found that sennoside A and ceftazidime, two small molecules, can inhibit RNA binding in the nucleocapsid proteins of SARS-CoV-2, SARS-CoV, and MERS-CoV in laboratory experiments. The nucleocapsid protein is highly conserved across coronaviruses and essential for viral replication, making it a potential drug target. The findings suggest these compounds could form the basis for pan-coronavirus antiviral therapies, though further development and clinical testing would be needed.